Australia's most trusted
source of pharma news
Wednesday, 29 October 2025
Posted 28 October 2025 AM
The explosive growth in the PD-1/PD-L1 inhibitor market is expected to slow down over the next few years, but still hit a level which would be welcome in most other drug classes.
The Global Oncology Trends 2025 report released by IQVIA detailed the changing trends in growth in oncology spending across the globe, as the PD-1/PD-L1 market slows and China speeds up.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.